On November 22-23, 2024, the 2024 Jiangsu Provincial Medical Doctor Association Annual Conference of the Surgical Physicians and the 12th Jinling International Symposium on Advances in Gastric Cancer Diagnosis and Treatment, jointly organized by the Jiangsu Provincial Medical Doctor Association and its Surgical Physicians Branch and hosted by The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People’s Hospital), were grandly convened in Nanjing, a historic city.
This congress brought together dozens of leading experts and academic pioneers from national surgical, medical oncology, and pathology fields. Through diverse formats including keynote speeches, live surgical demonstrations, and panel discussions, the event conducted comprehensive explorations of gastrointestinal stromal tumor (GIST) diagnosis and treatment. It aimed to advance academic standards in China’s GIST management while injecting momentum into the field’s medical development, fostering collaborative innovation to elevate GIST diagnosis and treatment to new heights and horizons.
This conference focuses on minimally invasive tumor surgery utilizing laparoscopic and robotic techniques. In recent years, laparoscopic surgery has emerged as a groundbreaking approach in oncology, characterized by its minimally invasive methodology—accessing internal structures through small incisions and performing precise operations via advanced optical systems. Compared to traditional open surgery, this technology demonstrates significant advantages including reduced trauma, accelerated recovery, and fewer postoperative complications.
Furthermore, robotic-assisted technology has pioneered new frontiers in tumor resection surgery. Modern robotic surgical systems, characterized by unparalleled flexibility and precision, enable surgeons to perform intricate maneuvers with exceptional accuracy even in complex anatomical environments. By enhancing surgical precision and minimizing invasiveness, this technology has substantially elevated the quality and efficacy of tumor resection procedures, driving revolutionary advancements in oncological therapeutics and establishing new paradigms for minimally invasive cancer treatment.
As one of the leading high-tech enterprise representatives in the field of minimally invasive surgery, YMED is honored to be invited to this congress. At this event, the company showcased its latest self-developed minimally invasive surgical consumables, which attracted widespread attention from experts and scholars.
